{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:35Z","timestamp":1791207335395,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"20","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venetoclax (VEN) inhibits the prosurvival protein BCL2 to induce apoptosis and is a standard therapy for chronic lymphocytic leukemia (CLL), delivering high complete remission rates and prolonged progression-free survival in relapsed CLL but with eventual loss of efficacy. A spectrum of subclonal genetic changes associated with VEN resistance has now been described. To fully understand clinical resistance to VEN, we combined single-cell short- and long-read RNA-sequencing to reveal the previously unappreciated scale of genetic and epigenetic changes underpinning acquired VEN resistance. These appear to be multilayered. One layer comprises changes in the BCL2 family of apoptosis regulators, especially the prosurvival family members. This includes previously described mutations in BCL2 and amplification of the MCL1 gene but is heterogeneous across and within individual patient leukemias. Changes in the proapoptotic genes are notably uncommon, except for single cases with subclonal losses of BAX or NOXA. Much more prominent was universal MCL1 gene upregulation. This was driven by an overlying layer of emergent NF-\u03baB (nuclear factor kappa B) activation, which persisted in circulating cells during VEN therapy. We discovered that MCL1 could be a direct transcriptional target of NF-\u03baB. Both the switch to alternative prosurvival factors and NF-\u03baB activation largely dissipate following VEN discontinuation. Our studies reveal the extent of plasticity of CLL cells in their ability to evade VEN-induced apoptosis. Importantly, these findings pinpoint new approaches to circumvent VEN resistance and provide a specific biological justification for the strategy of VEN discontinuation once a maximal response is achieved rather than maintaining long-term selective pressure with the drug.<\/jats:p>","DOI":"10.1182\/blood.2022016040","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T14:52:57Z","timestamp":1655391177000},"page":"2127-2141","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":94,"title":["Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-306X","authenticated-orcid":false,"given":"Rachel","family":"Thijssen","sequence":"first","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyi","family":"Tian","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"},{"name":"3Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Flensburg","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jarratt","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8312-8450","authenticated-orcid":false,"given":"Alexandra L.","family":"Garnham","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6302-4857","authenticated-orcid":false,"given":"Jafar S.","family":"Jabbari","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4813-0827","authenticated-orcid":false,"given":"Hongke","family":"Peng","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2432","authenticated-orcid":false,"given":"Thomas E.","family":"Lew","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"},{"name":"3Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis E.","family":"Teh","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5142-7886","authenticated-orcid":false,"given":"Quentin","family":"Gouil","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Georgiou","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-0360","authenticated-orcid":false,"given":"Tania","family":"Tan","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3527-1276","authenticated-orcid":false,"given":"Tirta M.","family":"Djajawi","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"3Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"4Department of Medicine, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"3Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"4Department of Medicine, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piers","family":"Blombery","sequence":"additional","affiliation":[{"name":"3Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"4Department of Medicine, University of Melbourne, Melbourne, Australia"},{"name":"5Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-8242","authenticated-orcid":false,"given":"Daniel H. D.","family":"Gray","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6087-635X","authenticated-orcid":false,"given":"Ian J.","family":"Majewski","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-0609","authenticated-orcid":false,"given":"Matthew E.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"},{"name":"3Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"6Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-4873","authenticated-orcid":false,"given":"David C. S.","family":"Huang","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2022111716253814000_bib1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","article-title":"Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax","volume":"7","author":"Leverson","year":"2017","journal-title":"Cancer Discov"},{"issue":"13","key":"2022111716253814000_bib2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2022111716253814000_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2022111716253814000_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2022111716253814000_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2022111716253814000_bib6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7626","key":"2022111716253814000_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"12","key":"2022111716253814000_bib8","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a Selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies [published correction appears in Cancer Discov. 2019;9(7):980]","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"issue":"25","key":"2022111716253814000_bib9","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2022111716253814000_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2022111716253814000_bib11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of\u00a0venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"2022111716253814000_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"2022111716253814000_bib13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"9","key":"2022111716253814000_bib14","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2\u00a0mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"2022111716253814000_bib15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2022111716253814000_bib16","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p\u00a0deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"2022111716253814000_bib17","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2022111716253814000_bib18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"2022111716253814000_bib19","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study [published correction appears in J Clin Oncol. 2020;38(14):1644]","volume":"37","author":"Hillmen","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2022111716253814000_bib20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood.2020009578","article-title":"Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy","volume":"138","author":"Ma","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2022111716253814000_bib21","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/bioinformatics\/btw777","article-title":"Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R","volume":"33","author":"McCarthy","year":"2017","journal-title":"Bioinformatics"},{"key":"2022111716253814000_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13059-016-0947-7","article-title":"Pooling across cells to normalize single-cell RNA sequencing data with many zero counts","volume":"17","author":"Lun","year":"2016","journal-title":"Genome Biol"},{"issue":"5","key":"2022111716253814000_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nbt.4091","article-title":"Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors","volume":"36","author":"Haghverdi","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2022111716253814000_bib24","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"issue":"43","key":"2022111716253814000_bib25","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2022111716253814000_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13059-021-02525-6","article-title":"Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing","volume":"22","author":"Tian","year":"2021","journal-title":"Genome Biol"},{"key":"2022111716253814000_bib27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nbt.4314","article-title":"Dimensionality reduction for visualizing single-cell data using UMAP","volume":"37","author":"Becht","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2022111716253814000_bib28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood.V70.2.418.418","article-title":"Normal cellular counterparts of B cell chronic lymphocytic leukemia","volume":"70","author":"Freedman","year":"1987","journal-title":"Blood"},{"issue":"2","key":"2022111716253814000_bib29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0092-8674(88)90382-0","article-title":"Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor","volume":"53","author":"Baeuerle","year":"1988","journal-title":"Cell"},{"issue":"2","key":"2022111716253814000_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc3204","article-title":"The diverse and complex roles of NF-\u03baB subunits in cancer","volume":"12","author":"Perkins","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"36","key":"2022111716253814000_bib31","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1038\/onc.2010.248","article-title":"Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40\/TLR9 triggering","volume":"29","author":"Tromp","year":"2010","journal-title":"Oncogene"},{"issue":"17","key":"2022111716253814000_bib32","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1182\/bloodadvances.2020003944","article-title":"Extrinsic interactions in the microenvironment in\u00a0vivo activate an antiapoptotic multidrug-resistant phenotype in CLL","volume":"5","author":"Jayappa","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2022111716253814000_bib33","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1128\/MCB.20.8.2687-2695.2000","article-title":"The Rel\/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L)","volume":"20","author":"Chen","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2022111716253814000_bib34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1101\/gad.13.4.382","article-title":"The prosurvival Bcl-2 homolog Bfl-1\/A1 is a direct transcriptional target of\u00a0NF-kappaB that blocks TNFalpha-induced apoptosis","volume":"13","author":"Zong","year":"1999","journal-title":"Genes Dev"},{"issue":"4","key":"2022111716253814000_bib35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","article-title":"Bcl-2\u00a0heterodimerizes in\u00a0vivo with a conserved homolog, Bax, that accelerates programmed cell death","volume":"74","author":"Oltvai","year":"1993","journal-title":"Cell"},{"issue":"7","key":"2022111716253814000_bib36","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"2022111716253814000_bib37","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","article-title":"BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models","volume":"35","author":"Zhao","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"2022111716253814000_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"9","key":"2022111716253814000_bib39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","article-title":"NF-\u03baB, an active player in human cancers","volume":"2","author":"Xia","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2022111716253814000_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","article-title":"Saga of Mcl-1: regulation from transcription to degradation","volume":"27","author":"Senichkin","year":"2020","journal-title":"Cell Death Differ"},{"issue":"7","key":"2022111716253814000_bib41","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"issue":"34","key":"2022111716253814000_bib42","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2022111716253814000_bib43","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2021-147731","article-title":"Assessment of the clonal dynamics of acquired mutations in patients (Pts) with relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL) treated in the randomized phase 3 Murano trial supports venetoclax-rituximab (VenR) fixed-duration combination treatment (Tx) [abstract]","volume":"138","author":"Seymour","year":"2021","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/20\/2127\/1982959\/blood_bld-2022-016040-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/20\/2127\/1982959\/blood_bld-2022-016040-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T11:50:04Z","timestamp":1675857004000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/20\/2127\/485591\/Single-cell-multiomics-reveal-the-scale-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":43,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2022,11,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022016040","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]}}}